Completed PHASE1 INTERVENTIONAL 2-arm NCT01897428

PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg

Clinical Trial to Evaluate Pharmacokinetic Characteristics of Belion in Healthy Subjects

Sponsor: Hanlim Pharm. Co., Ltd.

Conditions Allergic Rhinitis Pruritus Urticaria

Interventions Reference-bepotastine besilate 10 mg Test-Bepotastine salicylate 9.64 mg

Updated 6 times since 2017 Last updated: Jul 11, 2013 Started: Apr 30, 2011 Primary completion: May 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Allergic Rhinitis and Pruritus and is currently completed. Hanlim Pharm. Co., Ltd. leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hanlim Pharm. Co., Ltd.
Korea University Anam Hospital

Data source: Korea University Anam Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea